CureVac BV (CVAC) Stock Price Today
Key Stats
- $1.05BMarket Cap
- -Volume
- HealthSector
- $5.6052W High
- $2.5952W Low
- -Typical Hold Time
- $599.28MEnterprise Value
- -Div Yield
- -Trading Activity
Track CureVac BV (CVAC) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, CureVac BV has traded between a low of $2.59 and a high of $5.6, highlighting its annual price range. Buy and sell CureVac BV shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About CureVac BV
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid (mRNA). The company was founded in 2000 and had its initial public offering in August 2020. CureVac is collaborating with GlaxoSmithKline to develop a second-generation COVID-19 vaccine. CureVac's first attempt to develop a COVID-19 vaccine did not have sufficient efficacy data, and its trials were discontinued in October 2021. The company's other pipeline candidates include mRNA vaccines for influenza, rabies, and malaria. Additionally, CureVac is in the early stages of development for oncology and molecular therapies spanning tumors, liver, ocular, and lung diseases.
Most Recent News
New Deserve to Win Podcast episode features telecom CEOs discussing industry shakeup and legal updates.
The latest episode of Troutman Amin, LLP's Deserve to Win Podcast features interviews with CEOs from Contact Center Compliance, PureCaller ID, and Sonera, discussing the merger of CCC and PCID into Sonera and its impact on telecom industry consolidat...
EU approves Sanofi's MenQuadfi vaccine for infants from six weeks to prevent invasive meningococcal disease.
The European Commission has approved Sanofi's MenQuadfi vaccine for use in infants as young as six weeks old to protect against invasive meningococcal disease caused by serogroups A, C, W, and Y. Previously approved for those aged 12 months and older...
Nurix enrolls first patient in Phase 3 trial testing bexobrutideg vs pirtobrutinib for relapsed CLL/SLL
Nurix Therapeutics has enrolled the first patient in its global Phase 3 DAYBreak CLL-306 trial, comparing bexobrutideg, a targeted protein degrader, to pirtobrutinib in patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocyt...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.